The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | PHE885, a novel BCMA-directed CAR-T therapy for patients with R/R multiple myeloma
Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, explains how the PHE885 CAR-T construct differs from existing BCMA-directed CAR-T therapies and highlights the results of a Phase I trial evaluating this product at different dose levels (NCT04318327). Overall, the study reported early evidence of promising activity and expansion of the CAR-Ts in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
